Treatment of Deep Vein Thrombosis of the lower limb
Confirmatory diagnostic tests should be performed within 24 hours.
• In addition, for the prevention of postthrombotic syndrome (PTS), we recommend the use of an elastic compression stocking with an ankle pressure gradient of 30 to 40 mm Hg (usually type 2 compression) if feasible. Compression therapy, which may include the use of bandages acutely, should be started as soon as feasible* after starting anticoagulation and should be continued for a minimum of 2 years in case of symptomatic proximal DVT, and longer if patients have symptoms of PTS.
• We recommend early ambulation in preference to bed rest when this is feasible.
• Don't use VKA during pregnancy. Hereditary thrombophilia has not been used as a major factor to guide duration of anticoagulation for VTE in these recommendations because evidence from prospective studies suggests that these factors are not a major determinant of the risk of recurrence.
The concept of indefinite (or long-term) anticoagulation has been introduced with the following definition: continued anticoagulation without a scheduled stop date, but which may be stopped because of a subsequent increase in the risk of bleeding or change in the patient's preference. In selected patients with extensive iliofemoral acute DVT (eg. symptoms for less than 7 to 14 days, good functional status, life expectancy of ≥ 1 year), an alternative treatment may be suggested in the acute phase according to Table 2 . 
Treatment of Pulmonary embolism
Treatment regimens for DVT and PE are similar but there are some important differences between patients who present with PE and with DVT that justify separate consideration of treatment for PE:
• The risk of early death (within 1 month) is much greater after presenting with PE than after DVT; this difference may justify more agressive initial treatment (eg, thrombolytic therapy, insertion of an IVC filter).
• Recurrent episodes are about 3 times as likely to be PE after an initial PE than after an initial DVT.
• Long-term sequelae of PE are cardiorespiratory impairment, especially due to pulmonary hypertension.
All the patients presenting with PE should undergo rapid risk stratification to select those who could benefit from thrombolytic therapy.
The main recommendations for initial anticoagulant therapy do not differ for proximal DVT or PE (Table 3 ).
• For patients with a PE , we recommend an anticoagulant therapy:
o In case of an objectively confirmed PE, treatment as in • In selected high-risk patients without hypotension who are judged to have a low risk of bleeding, thrombolytic therapy can be considered. The decision to use thrombolytic therapy depends on the clinician's assessment of PE severity, prognosis, and risk of bleeding.
• For the majority of patients with PE, we recommend against using thrombolytic therapy.
• When a thrombolytic agent is used, we recommend that treatment be administered via a peripheral vein rather than placing a pulmonary artery catheter to administer treatment.
• We recommend use of thrombolytic regimens with short infusion times (eg, a 2-h infusion) over those with prolonged infusion times (eg, a 24-h infusion).
In selected highly compromised patients in the acute phase who are unable to receive thrombolytic therapy because of bleeding risk, an alternative treatment may be suggested according to Table 5 . For patients with acute PE who have an IVC filter inserted as an alternative to anticoagulation, we recommend that they should subsequently receive a conventional course of anticoagulant therapy if their risk of bleeding resolves.
For patients with chronic thromboembolic pulmonary hypertension, we recommend or suggest the following (Table 6 ). 
Treatment of Upper-extremity Deep Vein Thrombosis (UEDVT)
For patients with an UEDVT, we recommend an anticoagulant therapy for at least 3 months as described for lower limbs DVT (Table 1) .
Other recommendations and suggestions are given in Table 7 . We recommend anticoagulant therapy for ≥ 3 months (as described for DVT of the lower limb).
•
We recommend against the routine use of systemic or catheter-directed thrombolytic therapy.
We recommend against the routine use of catheter extraction, surgical thrombectomy, transluminal angioplasty, stent placement, staged approach of lysis followed by interventional or surgical procedure, or superior vena cava filter placement.
We suggest the following approach if UEDVT is associated with an indwelling catheter :
o the catheter has not to be removed if it is functional and there is an ongoing need for the catheter;
o if the catheter is removed, the duration of long-term anticoagulation has not to be shortened to less than 3 months.
